文献速递支持与姑息治疗

在不可治愈且正在接受抗癌治疗的癌症门诊患者人群中验证预后工具的临床研究:PRONOPALL研究

Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study.
PubMed 文献 · Ann Oncol · 2017-01-01

PRONOPALL是一项多中心现况研究,于2009年10月至2010年10月在16家机构纳入302例符合终末期标准的成人门诊癌症患者,前瞻性验证基于ECOG体能状态、转移部位数、血清白蛋白和乳酸脱氢酶的四因素预后工具。262例可评估患者按评分分为三组,2个月生存率分别为92%、66%和24%,中位生存分别为301天、79天和35天,三组生存差异有统计学意义(P<0.0001)。

要点

  • PRONOPALL预后工具基于ECOG体能状态、转移部位数、血清白蛋白和乳酸脱氢酶四项因素。
  • C组130例2个月生存率92%、中位生存301天;B组111例分别为66%和79天;A组21例分别为24%和35天。
  • 三组生存差异有统计学意义(P<0.0001),该评分可作为日常实践中的决策工具。

核心结论

  • PRONOPALL研究证实了由四项因素组合定义的三类预后人群,该评分是日常实践中有用的决策工具。

研究设计与样本

  • PRONOPALL为多中心现况研究(current care),于2009年10月至2010年10月在16家机构纳入302例成人门诊癌症患者。
  • 纳入标准为符合以下一项或多项:预期寿命不足6个月、体能状态≥2、前一化疗方案期间疾病进展。
  • 为验证预后工具,计算评分并与患者生存进行相关分析;262例(87%)可评估(排除27例,13例评分未知)。

主要发现

  • 中位年龄66岁[37-88],女性占59%;ECOG PS 0-1占46%、PS 2占37%、PS 3-4占17%。
  • 原发肿瘤为乳腺癌29%、结直肠癌28%、肺癌13%、胰腺癌12%、卵巢癌11%和其他8%。
  • 32%的患者有一个转移部位,35%有两个,31%有两个以上;乳酸脱氢酶中位水平398 IU/l[118-4314],血清白蛋白中位水平35 g/l[13-54]。
  • 按PRONOPALL预后工具,C组130例的2个月生存率为92%、中位生存301天[209-348];B组111例分别为66%和79天[71-114];A组21例分别为24%和35天[14-56]。
  • 三组人群生存差异有统计学意义(P<0.0001)。

关键数值与推荐

  • PRONOPALL预后工具的四项因素为:ECOG体能状态、转移部位数、血清白蛋白和乳酸脱氢酶。
  • C组130例:2个月生存率92%,中位生存301天[209-348]。
  • B组111例:2个月生存率66%,中位生存79天[71-114]。
  • A组21例:2个月生存率24%,中位生存35天[14-56]。
  • 三组生存差异P<0.0001。

临床怎么用

  • 作者认为PRONOPALL评分是日常实践中有用的决策工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2008, a study of the characteristics of hospitalised patients led to the development of a prognostic tool that distinguished three populations with significantly different 2-month survival rates. The goal of our study aimed at validating prospectively this prognostic tool in outpatients treated for cancer in terminal stage, based on four factors: performance status (ECOG) (PS), number of metastatic sites, serum albumin and lactate dehydrogenase. PATIENTS AND METHODS: PRONOPALL is a multicentre study of current care. About 302 adult patients who met one or more of the following criteria: life expectancy under 6 months, performance status ≥ 2 and disease progression during the previous chemotherapy regimen were included across 16 institutions between October 2009 and October 2010. Afterwards, in order to validate the prognostic tool, the score was ciphered and correlated to patient survival. RESULTS: Totally 262 patients (87%) were evaluable (27 patients excluded and 13 unknown score). Median age was 66 years [37-88], and women accounted for 59%. ECOG PS 0-1 (46%), PS 2 (37%) and PS 3-4 (17%). The primary tumours were: breast (29%), colorectal (28%), lung (13%), pancreas (12%), ovary (11%) and other (8%). About 32% of patients presented one metastatic site, 35% had two and 31% had more than two. The median lactate dehydrogenase level was 398 IU/l [118-4314]; median serum albumin was 35 g/l [13-54]. According to the PRONOPALL prognostic tool, the 2-month survival rate was 92% and the median survival rate was 301 days [209-348] for the 130 patients in population C, 66% and 79 days [71-114] for the 111 patients in population B, and 24% and 35 days for [14-56] the 21 patients in population A. These three populations survival were statistically different (P <0.0001). CONCLUSION: PRONOPALL study confirms the three prognostic profiles defined by the combination of four factors. This PRONOPALL score is a useful decision-making tool in daily practice.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Bourgeois H, Grudé F, Solal-Céligny P, et al. Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study. Ann Oncol. 2017. PMID: 28472235. doi:10.1093/annonc/mdx172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。